JP2014510152A5 - - Google Patents

Download PDF

Info

Publication number
JP2014510152A5
JP2014510152A5 JP2014504014A JP2014504014A JP2014510152A5 JP 2014510152 A5 JP2014510152 A5 JP 2014510152A5 JP 2014504014 A JP2014504014 A JP 2014504014A JP 2014504014 A JP2014504014 A JP 2014504014A JP 2014510152 A5 JP2014510152 A5 JP 2014510152A5
Authority
JP
Japan
Prior art keywords
formulation
viscosity
acetate
reduced
less
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2014504014A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014510152A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2012/032464 external-priority patent/WO2012141978A2/en
Publication of JP2014510152A publication Critical patent/JP2014510152A/ja
Publication of JP2014510152A5 publication Critical patent/JP2014510152A5/ja
Pending legal-status Critical Current

Links

JP2014504014A 2011-04-07 2012-04-06 粘度が低減された処方物 Pending JP2014510152A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161473123P 2011-04-07 2011-04-07
US61/473,123 2011-04-07
PCT/US2012/032464 WO2012141978A2 (en) 2011-04-07 2012-04-06 Formulations with reduced viscosity

Publications (2)

Publication Number Publication Date
JP2014510152A JP2014510152A (ja) 2014-04-24
JP2014510152A5 true JP2014510152A5 (enExample) 2015-05-21

Family

ID=47009919

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014504014A Pending JP2014510152A (ja) 2011-04-07 2012-04-06 粘度が低減された処方物

Country Status (12)

Country Link
US (1) US20140044727A1 (enExample)
EP (1) EP2694708A4 (enExample)
JP (1) JP2014510152A (enExample)
KR (1) KR20140066124A (enExample)
CN (1) CN103582724A (enExample)
AU (1) AU2012243126A1 (enExample)
BR (1) BR112013025845A2 (enExample)
CA (1) CA2832560A1 (enExample)
EA (1) EA201391489A1 (enExample)
IL (1) IL228626A0 (enExample)
SG (1) SG193964A1 (enExample)
WO (1) WO2012141978A2 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI3295957T1 (sl) * 2010-01-15 2020-02-28 Kirin-Amgen, Inc. Formulacija protitelesa proti IL-17RA in terapevtski režim za zdravljenje luskavice
WO2012138958A1 (en) * 2011-04-07 2012-10-11 Glaxosmithkline Llc Formulations with reduced viscosity
MX2014014717A (es) * 2012-06-21 2015-03-06 Ucb Pharma Sa Formulacion farmaceutica.
FR2994390B1 (fr) 2012-08-10 2014-08-15 Adocia Procede d'abaissement de la viscosite de solutions de proteines a concentration elevee
UA117466C2 (uk) 2012-12-13 2018-08-10 Мерк Шарп Енд Доме Корп. СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19
IL312865B2 (en) 2013-09-11 2025-06-01 Eagle Biologics Inc Liquid protein formulations containing viscosity-lowering agents
SG11201702614SA (en) 2014-10-01 2017-04-27 Eagle Biolog Inc Polysaccharide and nucleic acid formulations containing viscosity-lowering agents
CN116327922A (zh) 2015-08-24 2023-06-27 葛兰素史密斯克莱知识产权(第2 号)有限公司 生物医药组合物
CN105733250B (zh) * 2016-05-04 2017-12-26 山东省药学科学院 一种交联聚谷氨酸悬浮液及其制备方法与应用
CN110167531B (zh) * 2017-01-11 2025-06-03 赛特瑞恩股份有限公司 稳定的液体调配物
US11603407B2 (en) 2017-04-06 2023-03-14 Regeneron Pharmaceuticals, Inc. Stable antibody formulation
HRP20240167T1 (hr) 2017-04-28 2024-04-26 Amgen Inc. Formulacije ljudskih anti-rankl protutijela i postupci njihove upotrebe
RU2019138507A (ru) 2017-05-02 2021-06-02 Мерк Шарп И Доум Корп. Составы антител против lag3 и совместные составы антител против lag3 и антител против pd-1
JOP20190260A1 (ar) 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
WO2018211517A1 (en) 2017-05-16 2018-11-22 Bhami's Research Laboratory, Pvt. Ltd. High concentration protein formulations with reduced viscosity
WO2018226339A1 (en) * 2017-06-06 2018-12-13 Glaxosmithkline Llc Biopharmaceutical compositions and methods for pediatric patients
IL277095B2 (en) * 2018-03-07 2025-10-01 Pfizer Preparations containing anti-PD-1 antibody
CN113056482A (zh) 2018-10-18 2021-06-29 默沙东公司 抗rsv抗体的制剂及其使用方法
CN120842406A (zh) 2018-10-31 2025-10-28 默沙东有限责任公司 抗人pd-1抗体晶体及其使用方法
KR20210089215A (ko) 2018-11-07 2021-07-15 머크 샤프 앤드 돔 코포레이션 항-lag3 항체 및 항-pd-1 항체의 공동-제제
US12599669B2 (en) * 2019-04-23 2026-04-14 Amgen Inc. Use of low molecular weight polyvinylpyrrolidone (PVP) to reduce viscosity of high concentration protein formulations
GB202102258D0 (en) * 2021-02-17 2021-03-31 Arecor Ltd Novel composition

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4340062B2 (ja) * 2000-10-12 2009-10-07 ジェネンテック・インコーポレーテッド 粘度の減少した濃縮タンパク質製剤
US20050164929A1 (en) * 2000-11-06 2005-07-28 Lupine Logic, Inc. Methods of preventing and treating inflammatory bowel disease
MXPA05004528A (es) * 2002-11-01 2005-07-26 Glaxosmithkline Biolog Sa Composicion inmunogenica.
WO2004060343A1 (en) * 2002-12-31 2004-07-22 Nektar Therapeutics Antibody-containing particles and compositions
PL1942939T5 (pl) * 2005-09-30 2021-10-11 Medimmune Limited Kompozycja przeciwciała interleukiny-13
JP5405122B2 (ja) * 2005-12-21 2014-02-05 ワイス・エルエルシー 低粘度のタンパク質製剤およびその用途
JP5231810B2 (ja) * 2005-12-28 2013-07-10 中外製薬株式会社 抗体含有安定化製剤
EP2173163A4 (en) * 2007-07-06 2010-12-08 Glaxosmithkline Llc ANTIBODY FORMULATIONS
UA107557C2 (xx) * 2007-07-06 2015-01-26 Композиція антитіла офатумумабу
AU2008304111B2 (en) * 2007-09-27 2014-04-24 Amgen Inc. Pharmaceutical formulations
PE20091174A1 (es) * 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd Formulacion liquida con contenido de alta concentracion de anticuerpo
BR112012013093A2 (pt) * 2009-12-21 2017-12-12 Genentech Inc ''formulação farmacêutica aquosa estável, artigo, métodos para estabilizar um anticorpo, para tratamento de uma doença ou distúrbio em um indivíduo, para reduzir a agregação de um anticorpo monoclonal terapêutico e de fabricação de uma formulação farmaceutica, frasco e tanque de aço inoxidável
CN102958538A (zh) * 2010-05-03 2013-03-06 弗·哈夫曼-拉罗切有限公司 用于降低含有蛋白质的制剂的粘度的组合物和方法

Similar Documents

Publication Publication Date Title
JP2014516924A5 (enExample)
RU2020123963A (ru) Стабилизированные препараты, содержащие антитела против ngf
JP2020537520A5 (enExample)
JP2019503349A5 (enExample)
JP2013543505A5 (enExample)
IL283424B2 (en) Stabilized formulations that include antibodies against the interleukin receptor (il-4r)
RU2016129624A (ru) Биспецифичные антитела против гаптена/против рецептора гематоэнцефалического барьера, их комплексы и их применение в качестве челноков гематоэнцефалического барьера
IL274846B2 (en) Formulation for anti-alpha 4 antibody in cell 7
RU2012131671A (ru) Способ полипептидной модификации для очистки полипептидных мультимеров
RU2013155695A (ru) Препараты антител против с-мет
NZ627859A (en) Stabilized formulations containing anti-ang2 antibodies
UA107211C2 (uk) Стабілізовані склади, які містять антитіла до рецептора інтерлейкіну 6 (il-6r)
PE20241623A1 (es) Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y usos de los mismos
JP2017515909A5 (enExample)
MX363226B (es) Formulaciones de anticuerpos.
JP2013535190A5 (enExample)
RU2015137685A (ru) Композиции антитела в низкой концентрации
JP2014522843A5 (enExample)
EA200970880A1 (ru) Стабильные композиции на основе антител
RU2015123476A (ru) Стабильные составы антител против рецептора программируемой смерти pd-1 человека и относящиеся к ним способы лечения
JP2014502955A5 (enExample)
AR088455A1 (es) Anticuerpos que antagonizan cd40l
HRP20192346T1 (hr) Molekule anti-lag-3 antitijela i njihove uporabe
FI3355919T3 (fi) Yhdistelmähoito ihmisen kasvu- ja erilaistumistekijä 15:n (GDF-15) inhibiittoreita ja immuunitarkistuspiste-estäjiä käyttämällä
JP2016539096A5 (enExample)